alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<PAGE>   1

                                                                     EXHIBIT 3.2


                            CERTIFICATE OF AMENDMENT
                                       OF
                          CERTIFICATE OF INCORPORATION
                                       OF
                    A I M MANAGEMENT GROUP ACQUISITION CORP.


        Pursuant to Section 242 of the Delaware General Corporation Law


                 A I M MANAGEMENT GROUP ACQUISITION CORP. (the "Corporation"),
a corporation organized and existing under and by virtue of the Delaware
General Corporation Law, DOES HEREBY CERTIFY:

                 FIRST:  That at a meeting of the Board of Directors of the
Corporation, resolutions were duly adopted proposing and declaring advisable
the following amendment to the Certificate of Incorporation of the Company:

                 RESOLVED, that Article FIRST of the Corporation's Certificate
         of Incorporation be amended to read in full as follows:

                           "FIRST:  The name of the corporation is A I M 
                           Management Group Inc."

                 SECOND:  That thereafter the holders of the stock of the
Corporation entitled to vote thereon voted in favor of the amendment by written
consent in accordance with Section 228 of the General Corporation Law.

                 THIRD:  That the foregoing amendment to the Certificate of
Incorporation was duly adopted in accordance with the provisions of Section 242
of the General Corporation Law.

                 IN WITNESS WHEREOF, A I M Management Group Acquisition Corp.
has caused this Certificate to be executed by its duly authorized officers this
28th day of February, 1997.

                                       A I M MANAGEMENT GROUP ACQUISITION CORP.


                                       By: /s/ ROBERT H. GRAHAM
                                           --------------------------
                                       Name:   Robert H. Graham
                                            -------------------------
                                       Title:  President and Chief 
                                               Executive Officer
                                             ------------------------
# U n i ted S t a te s C ou r t o f Appe a l s F OR T HE D IS TRICT OF C OLUM BIA C IRCUI T

___ ___ ___ ___ 

## No. 20-5277 September Term, 2020 1: 20-c v -018 98-UNA Filed O n: Februa ry

8, 202 1 Charles L . St ringer,

App ellant
v . John Downy , etal.,

App ellees ON A PPE A L FROM THE UNITED STA TES DIS TRICT COURT FOR THE DISTRICT OF COLUMBIA BEFORE: Hend erson an d K atsa s, Circuit Jud ges, an d S ent elle, S enio r Circuit

Judge J U D G M E N T T his ap pea l was co nside red o n th e reco rd f rom the United Sta tes District Cou rt for th e District of

Colum bia a nd on the brief f iled b y ap pellan t. S ee Fed. R. Ap p. P

. 34(a )(2); D.C. Cir. Rule 34 (j). It is ORDERED A ND A DJUDGED tha t th e d istrict court’s o rders f iled Ju ly 27 , 20 20 and Au gust 18 , 20 20, be af f irmed . T he district cou rt prop erly dism issed t he case w ithou t prejudice for lack o f subject m atte r jurisdiction. Se e Deca tur L iquors, Inc. v. District of

Colum bia, 478 F.3d 36 0, 3 63 (D.C. Cir. 2007 ) (fe dera l courts lack subject ma tter ju risdiction o v er “obviously frivolou s” claims); S ma lls v . Unite d S tate s, 47 1 F.3 d 186 , 19 2 (D.C. Cir. 20 06) (“A fede ral district cou rt lacks jurisdiction to rev iew de cisions of oth er fede ral cou rts.”). T he dism issal w ithou t prejudice allows appe llant t o f ile a n ew com plaintin th e a ppro priate m ann er. S ee Com m. for Ef fective Cellular Rules v . FCC, 53 F.3d 13 09, 13 18 (D.C. Cir. 1995 ). In ad dition , ap pellan t can notcom pel a crimina l investig ation by f iling a com plaintin d istrict court. Cf . W indso r v . Evans, 403 F. Ap p'x 527 , 52 8 (D.C. Cir. 20 10) (“[A] gov ernm entof f icial’s decision w het her t o investigate a nd prose cute a ca se is within the un rev iewable discretio n o f the Executive Branch .”). Last ly , ap pellan t ha s no t de mo nstrat ed tha t th e d istrict court a buse d its d iscretion by dism issing his claims w ithou t allowing discovery , or in de nying his m otion to alter o r am end the judgm ent . S ee, e.g., Fo od Lion , In c. v. United Food & Co mm ercial W orkers Int'l Un ion, AFL-CIO-CLC, 1 03 F.3d 10 07, 10 12 (D.C. Cir. 1997 ); Fireston e v. Firestone , 76 F.3d 12 05, 12 08 (D.C. Cir. 1996 ) (per curiam ).

# U n i ted S t a te s C ou r t o f Appe a l s F OR T HE D IS TRICT OF C OLUM BIA C IRCUI T

___ ___ ___ ___ 

## No. 20-5277 September Term, 2020
Pursua nt t o D.C. Circuit Ru le 36 , th is dispo sition will no t be pu blished . T he Clerk is directe d to w ithho ld issua nce of the m and ate he rein u ntil seven d ays af ter reso lution of an y tim ely petition for rehe aring or pe tition for rehe aring en ban c. S ee Fed. R. Ap p. P. 4 1(b); D.C. Cir. Rule 41

. Per Curiam FOR THE COURT: Mark J. La nger, Clerk BY: /s/ Daniel J. Reidy Depu ty Cl erk

Page 2
Mitchell J. STEIN, petitioner, v. CALIFORNIA.

No. 18-605.

Supreme Court of the United States

Jan. 7, 2019.

Petition for writ of certiorari to the Court of Appeal of California, Second Appellate District denied.
1

United States District Court

EASTERN DISTRICT OF TEXAS

SHERMAN DIVISION

ADNAN UMAIR JANJUA-VESSEL AND 

UZMA JANJUA-VESSEL

V.

JAY BRAY, et al.

§

§

§

§

§

§

§

CIVIL ACTION NO. 4:23CV766

JUDGE MAZZANT/JUDGE JOHNSON

MEMORANDUM ADOPTING REPORT AND

RECOMMENDATION OF UNITED STATES MAGISTRATE JUDGE

Came on for consideration the report of the United States Magistrate Judge in this action, 

this matter having been heretofore referred to the Magistrate Judge pursuant to 28 U.S.C. § 636. 

On February 27, 2024, the report of the Magistrate Judge (the “Report”) (Dkt. #48) was entered 

containing proposed findings of fact and recommendations that Plaintiffs Adnan Umair JanjuaVessel and Uzma Janjua-Vessel’s (“Plaintiffs”) Motion to Stay for All Non-Judicial Proceedings 

(Dkt. #4) be denied. On March 12, 2024, Plaintiffs filed objections (the “Objections”) (Dkt. #50) 

to the Report (Dkt. #48), to which Defendant Nationstar Mortgage LLC filed a response (the 

“Response”) (Dkt. #52).

The Court has conducted a de novo review of the Objections (Dkt. #50) and is of the 

opinion that the findings and conclusions of the Magistrate Judge are correct, and the Objections

(Dkt. #50) are without merit as to the ultimate findings of the Magistrate Judge. Accordingly, 

Plaintiffs’ Objections (Dkt. #50) are OVERRULED and the Magistrate Judge’s Report (Dkt. #48)

is ADOPTED as the findings and conclusions of the Court.

IT IS ORDERED that the Motion to Stay for All Non-Judicial Proceedings (Dkt. #4) is 

hereby DENIED.

Case 4:23-cv-00766-ALM-KPJ Document 53 Filed 03/28/24 Page 1 of 2 PageID #: 321
2

Case 4:23-cv-00766-ALM-KPJ Document 53 Filed 03/28/24 Page 2 of 2 PageID #: 322
```
  
 
VIX FUTURES - CBOE FUTURES EXCHANGE                                  Code-1170E1
OPTION AND FUTURES COMBINED POSITIONS AS OF 05/08/12          |
--------------------------------------------------------------| NONREPORTABLE
      NON-COMMERCIAL      |   COMMERCIAL    |      TOTAL      |   POSITIONS
--------------------------|-----------------|-----------------|-----------------
  Long  | Short  |Spreads |  Long  | Short  |  Long  | Short  |  Long  | Short
--------------------------------------------------------------------------------
($1000 X INDEX)                                      OPEN INTEREST:      326,785
COMMITMENTS
  74,427  111,036   41,220  186,530  148,740  302,177  300,996   24,608   25,789

CHANGES FROM 05/01/12 (CHANGE IN OPEN INTEREST:      7,992)
 -11,834   -3,170    3,389   13,179    3,248    4,734    3,467    3,258    4,525

PERCENT OF OPEN INTEREST FOR EACH CATEGORY OF TRADER
    22.8     34.0     12.6     57.1     45.5     92.5     92.1      7.5      7.9

NUMBER OF TRADERS IN EACH CATEGORY (TOTAL TRADERS:      131)
      28       56       56       30       38       97      120
```

----

Updated May 11, 2012
IN THE UNITED STATES DISTRICT COURT

FOR THE EASTERN DISTRICT OF TEXAS

BEAUMONT DIVISION

SHAWN HAWES §

VS. § CIVIL ACTION NO. 1:23-CV-52

 

WARDEN, FCI BEAUMONT §

ORDER ADOPTING THE MAGISTRATE

JUDGE’S REPORT AND RECOMMENDATION

Plaintiff Shawn Hawes, a prisoner confined at the Federal Correctional Institution in

Beaumont, Texas, proceeding pro se, filed this petition for writ of habeas corpus pursuant to 28

U.S.C. § 2241.

The Court referred this matter to the Honorable Zack Hawthorn, United States Magistrate

Judge, at Beaumont, Texas, for consideration pursuant to applicable laws and orders of this Court. 

On March 4, 2024, the magistrate judge recommended denying the petition. To date, the parties

have not filed objections to the report and recommendation.

The Court received and considered the Report and Recommendation of United States

Magistrate Judge pursuant to such referral, along with the record, pleadings and all available

evidence. Proper notice was given to Petitioner at his last known address. See FED. R. CIV. P.

5(b)(2)(C). After careful review, the Court finds that the findings of fact and conclusions of law of

the United States Magistrate Judge are correct. 

ORDER

Accordingly, the findings of fact and conclusions of law of the magistrate judge are correct,

and the Report and Recommendation of United States Magistrate Judge [Dkt. 8] is ADOPTED. A

Case 1:23-cv-00052-MJT-ZJH Document 10 Filed 03/25/24 Page 1 of 2 PageID #: 103
final judgment will be entered in this case in accordance with the magistrate judge’s

recommendation. 

2

____________________________

Michael J. Truncale

United States District Judge SIGNED this 25th day of March, 2024.

Case 1:23-cv-00052-MJT-ZJH Document 10 Filed 03/25/24 Page 2 of 2 PageID #: 104
**Exhibit 31.01**
**GUILFORD PHARMACEUTICALS INC.****CERTIFICATION OF CHIEF EXECUTIVE OFFICER**
I, Craig R. Smith, M.D., certify that:
1. I have reviewed this annual report on Form 10-K, asamended, of Guilford Pharmaceuticals Inc.;
2. Based on my knowledge, this report does not contain anyuntrue statement of a material fact or omit to state a materialfact necessary to make the statements made, in light of thecircumstances under which such statements were made, notmisleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, andother financial information included in this report, fairlypresent in all material respects the financial condition,results of operations and cash flows of the registrant as of,and for, the periods presented in this report;
4. The registrant’s other certifying officer and I areresponsible for establishing and maintaining disclosure controlsand procedures (as defined in Exchange Act Rules 13a-15(e)and 15d-15(e)) for the registrant and have:
     (a) Designed such disclosure controls and procedures, orcaused such disclosure controls and procedures to be designedunder our supervision, to ensure that material informationrelating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within thoseentities, particularly during the period in which this report isbeing prepared;
     (b) [Paragraph reserved pursuant to SECRelease 33-8238];
     (c) Evaluated the effectiveness of the registrant’sdisclosure controls and procedures and presented in this reportour conclusions about the effectiveness of the disclosurecontrols and procedures, as of the end of the period covered bythis report based on such evaluation; and
     (d) Disclosed in this report any change in theregistrant’s internal control over financial reporting thatoccurred during the registrant’s most recent fiscal quarter(the registrant’s fourth fiscal quarter in the case of anannual report) that has materially affected, or is reasonablylikely to materially affect, the registrant’s internalcontrol over financial reporting; and
5. The registrant’s other certifying officer and Ihave disclosed, based on our most recent evaluation of internalcontrol over financial reporting, to the registrant’sauditors and the audit committee of the registrant’s boardof directors (or persons performing the equivalent functions):
     (a) All significant deficiencies and material weaknesses inthe design or operation of internal control over financialreporting which are reasonably likely to adversely affect theregistrant’s ability to record, process, summarize andreport financial information; and
     (b) Any fraud, whether or not material, that involvesmanagement or other employees who have a significant role in theregistrant’s internal control over financial reporting.
Date: April 9, 2004
    /s/ CRAIG R. SMITH, M.D.      Craig R. Smith, M.D. *Chairman, President and Chief Executive Officer*
Boulder YOUNG, aka Boulder Daniel McManigal, petitioner, v. UNITED STATES.

No. 19-920

Supreme Court of the United States.

Feb. 24, 2020

Petition for writ of certiorari to the United States Court of Appeals for the Eighth Circuit denied.
[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Page 29383]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-10239]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Medical CBRN Defense Consortium

    Notice is hereby given that, on April 7, 2022, pursuant to Section 
6(a) of the National Cooperative Research and Production Act of 1993, 
15 U.S.C. 4301 et seq. (``the Act''), Medical CBRN Defense Consortium 
(``MCDC'') has filed written notifications simultaneously with the 
Attorney General and the Federal Trade Commission disclosing changes in 
its membership. The notifications were filed for the purpose of 
extending the Act's provisions limiting the recovery of antitrust 
plaintiffs to actual damages under specified circumstances.
    Specifically, 7 Hills Pharma LLC, Houston, TX; Aleph Therapeutics, 
Inc., Stanford, CA; Amaratek, San Diego, CA; Applied Research 
Associates, Inc.; Albuquerque, NM; Horizons Global Solutions LLC; 
Purcellville, VA; Icahn School of Medicine at Mount Sinai; New York, 
NY; Iowa State University of Science and Technology; Ames, IA; 
Mainstream Engineering Corporation; Rockledge, FL; Najit Technologies, 
Inc.; Beaverton, OR; National Strategic Research Institute; Lincoln, 
NE; POP Biotechnologies, Inc.; Buffalo, NY; The Henry M. Jackson 
Foundation for the Advancement of Military Medicine; Bethesda, MD; 
University of Massachusetts; Lowell, MA and Virion Therapeutics LLC; 
Newark, DE have been added as parties to this venture.
    Also, Aardvark Medical, Inc., Ross, CA; Cytonus Therapeutics, Inc., 
Columbus, OH; Entasis Therapeutics, Waltham, MA; EUSA Pharma (US) LLC, 
Burlington, MA; GeneCapture, Inc., Huntsville, AL; and Visby Medical, 
Inc., San Jose, CA, have withdrawn as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and MCDC intends to file additional 
written notifications disclosing all changes in membership.
    On November 13, 2015, MCDC filed its original notification pursuant 
to Section 6(a) of the Act. The Department of Justice published a 
notice in the Federal Register pursuant to Section 6(b) of the Act on 
January 6, 2016 (81 FR 513).
    The last notification was filed with the Department on January 10, 
2022. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on March 10, 2022 (87 FR 13756).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-10239 Filed 5-12-22; 8:45 am]
BILLING CODE P
Exhibit
32.2





CERTIFICATION
OF CHIEF FINANCIAL OFFICER PURSUANT


TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the Annual Report of
NN, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2009,
as filed with the Securities and Exchange Commission on the date hereof (the
“Report”), the undersigned, in the capacity and date indicated below, hereby
certifies pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the
Sarbanes-Oxley Act of 2002, that, to my knowledge: (1) The Report fully complies
with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act
of 1934 as amended; and (2) The information contained in the Report fairly
presents, in all material respects, the financial condition and results of
operations of the Company.








Date:  March
31, 2010





/s/ James H.
Dorton


James H. Dorton


Vice President – Corporate Development
and Chief Financial Officer








[A signed
original of this written statement required by Section 906 has been provided to
NN, Inc. and will be retained by NN, Inc. and furnished to the Securities and
Exchange Commission or its staff upon request.]
Exhibit 31.1



CERTIFICATIONS



I, R. Carl Palmer, Jr., certify that:



1.

I have reviewed this annual report on Form 10-K/A of Pointe Financial Corporation;



2.

Based on my knowledge, this annual report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this annual report;



3.

Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report;



4.

The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:



(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared;



(b) Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this annual report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this annual report based on such evaluation; and



(c) Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and



5.

The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions);



(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting.



Date: April 29, 2005

By: /s/ R. CARLPALMER, JR.

R. Carl Palmer, Jr., Chairman of the Board,

President and Chief Executive Officer
1

United States District Court

EASTERN DISTRICT OF TEXAS

SHERMAN DIVISION

BLAKE WATTERSON,

Plaintiff,

v. 

BUREAU OF ALCOHOL, TOBACCO, 

FIREARMS AND EXPLOSIVES et al., 

Defendants. 

§

§

§

§

§

§

§

§

Civil Action No. 4:23-cv-00080

Judge Mazzant

ORDER

On May 23, 2024, Plaintiff filed his Unopposed Motion to Withdraw Motion for Summary 

Judgment (Dkt. #65). On the same day, Defendants filed their Response to Plaintiff’s Motion to 

Withdraw Motion for Summary Judgment (Dkt. #66). In their Response, Defendants indicate that 

they are unopposed to Plaintiff’s motion to withdraw but additionally request that the Court stay 

proceedings pending “the resolution of both Watterson’s appeal, 5th Cir. 23-40556, and the 

consolidated appeals challenging the Final Rule, Mock v. Garland, 5th Cir. 23-11157” (Dkt. #66 at 

pp. 1–2). 

Therefore, it is ORDERED that this case is stayed pending further proceedings.

IT IS SO ORDERED.

Case 4:23-cv-00080-ALM Document 68 Filed 06/17/24 Page 1 of 1 PageID #: 1111
Rebecca Joy OWENS, petitioner, v. LOUISIANA.

No. 17-8666.

Supreme Court of the United States

Oct. 1, 2018.

Petition for writ of certiorari to the Supreme Court of Louisiana denied.
<TABLE> <S> <C>

<ARTICLE> 5
<MULTIPLIER> 1000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               SEP-30-1997
<CASH>                                          38,786
<SECURITIES>                                         0
<RECEIVABLES>                                    5,012
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                     0
<PP&E>                                       2,296,271
<DEPRECIATION>                                 152,676
<TOTAL-ASSETS>                               2,279,267
<CURRENT-LIABILITIES>                                0
<BONDS>                                      1,157,863
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    126,013
<COMMON>                                             4
<OTHER-SE>                                     823,772
<TOTAL-LIABILITY-AND-EQUITY>                 2,279,267
<SALES>                                              0
<TOTAL-REVENUES>                               226,191
<CGS>                                                0
<TOTAL-COSTS>                                   61,591
<OTHER-EXPENSES>                                46,712
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              36,457
<INCOME-PRETAX>                                 76,974
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                             83,587
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    74,337
<EPS-PRIMARY>                                     1.59
<EPS-DILUTED>                                        0
        

</TABLE>